Expired Research Opportunities
Clinical Evaluation
Initiatives to evaluate biodefense therapies, vaccines, and diagnostics. This page includes EXPIRED funding opportunities only.
Relevant Date: January 22, 2008
Focus: To fund organizations with demonstrated vaccine product development experience to produce a vaccine candidate either for a NIAID Category A or B Priority Pathogen (PART A) or a candidate third generation anthrax vaccine (PART B).
Contact Info
Jordan Pulaski
Email: jpulaski@niaid.nih.gov
Relevant Date: December 18, 2007
Focus: To support the development of a prophylactic multivalent filovirus vaccine that is capable of protecting against both Ebola and Marburg viruses, utilizing platform technology such that the same basic development and manufacturing process is used to develop each component of the final multivalent vaccine.
Contact Info
Heidi Holley
Email: holleyh@niaid.nih.gov
Focus: To support projects to advance the development of promising candidate therapeutics with demonstrated in vivo activity against NIAID biodefense priority pathogens.
Contact Info
Suzanne Dawkins
E-mail: DLisle@niaid.nih.gov
Focus: To provide and manage a Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases which will operate under Good Clinical Practice (GCP) and will support an electronic data capture system.
Contact Info
David Lisle
Email: DLisle@niaid.nih.gov
Focus: For the establishment and management of a Statistical and Data Coordinating Center (SDCC) to support DMID's extramural clinical research programs, including studies on potential agents of bioterrorism and emerging and re-emerging infectious diseases.
Contact Info
Debby Baca
E-mail: dbaca@niaid.nih.gov
Focus: To support the development and testing of an anthrax vaccine candidate that improves upon the second generation anthrax vaccines by possessing the following characteristics: (1) should be suitable for storage in the Strategic National Stockpile, (2) should elicit a rapid immune response, (3) and should utilize a platform that shall allow non-technical persons to perform inoculations or self-administration.
Contact Info
Ross Kelley
E-mail: rkelley@niaid.nih.gov
Focus: To advance the development of candidate therapeutics with: (1) demonstrated activity against one or more of the selected NIAID Category A and B biothreat bacterial pathogens; or (2) broad spectrum activity against any of the Category C antimicrobial resistant pathogens and one more of the selected Category A and B bacterial pathogens. Product development shall be via a focused, staged approach and include candidate therapeutics within the regulatory purview of the Center for Drug Evaluation and Review (CDER) of the U.S. Food and Drug Administration (FDA).
Contact Info
Carl Newman
E-mail: cnewman@niaid.nih.gov
Focus: To develop new, safe, and effective therapeutics for Variola major and viral hemorrhagic fevers, viral encephalitides, and influenza.
Contact Info
Liem Nguyen
E-mail: ln18x@nih.gov
back to top